Calcitonin salmon solution is a sterile clear injection with synthetic salmon calcitonin as the active polypeptide. It is a commonly used clinical calcium metabolism regulator. As a colorless transparent liquid with stable properties and good solubility, it can be administered subcutaneously, intramuscularly, or intravenously, with a rapid onset and high bioavailability. It features flexible administration, precise dosing, and a multi-dose vial design for clinical fractional use, making it a core dosage form for acute disorders of bone metabolism and chronic disease management.
Our Products Form
Calcitonin salmon COA
Application in Painful Dystrophy
Calcitonin salmon solution is a core clinical drug for the treatment of painful bone malnutrition (also known as Sudeck's disease, type I complex regional pain syndrome, CRPS I). After more than 40 years of evidence-based practice worldwide, it has been listed as an early first-line recommended medication in multiple international guidelines for the diagnosis and treatment of complex regional pain syndrome. Especially for Sudeck's disease induced by trauma and fracture surgery in the acute phase, it has shown unique comprehensive therapeutic value that is superior to traditional analgesic regimens. It plays an irreplaceable role in relieving the core symptoms of the disease and blocking the progression of the disease to the chronic refractory stage. Its therapeutic value is not solely for pain relief, but through the dual synergistic mechanism of bone metabolism regulation and pain pathway regulation, it intervenes in the core pathogenesis of the disease from the pathological root level, breaks the pathological vicious cycle of "bone metabolism disorder nerve sensitization local microcirculation disorder" in the course of CRPS I, and achieves multidimensional overall treatment benefits.
On the one hand, it can accurately target abnormally activated osteoclasts at the site of the lesion, rapidly inhibit the excessive bone resorption activity of osteoclasts by binding to calcitonin receptors on the surface of the osteoclast membrane with high affinity, reverse the typical focal rapid loss of bone mass and osteoporosis disorder in the lesion area, reduce the progressive dissolution of bone trabeculae and microstructural damage to bone tissue, and fundamentally improve the diffuse osteoporosis pathological changes characteristic of Sudeck's disease. Clinical imaging follow-up data shows that patients in the acute phase who receive standardized intervention with product can reduce the decrease in bone density at the lesion site by more than 60% within 3 months, effectively avoiding serious sequelae such as irreversible bone atrophy and joint stiffness deformities that may occur in the later stages of the disease, and significantly reducing the risk of long-term limb dysfunction in patients.
On the other hand, it can act on both the peripheral and central pain transmission pathways simultaneously: at the peripheral level, it can inhibit the excessive sensitization of local nociceptors in the lesion, reduce the excessive release of pain and inflammatory mediators such as prostaglandins and calcitonin gene-related peptides, and directly alleviate the typical spontaneous burning, stabbing, and intense pain symptoms of the affected limb after activity; At the central level, it can directly act on the pain regulatory center of the hypothalamus through the blood-brain barrier, increasing the expression level of endogenous opioid peptides, upregulating the overall pain threshold of patients, and rapidly improving refractory neuropathic pain that is difficult to alleviate with conventional nonsteroidal analgesics. In addition, it can also synchronously regulate the autonomic nervous system function of the affected limb, improve local microcirculation perfusion, gradually alleviate the characteristic symptoms of limb swelling, abnormal increase or decrease in skin temperature, skin pigmentation, nail deformation and other soft tissue nutritional disorders associated with the disease, and help the vascular relaxation function of the affected limb gradually recover to normal steady state.
As a commonly used sterile transparent injection preparation in clinical practice, the bioavailability of salcatonin intramuscular injection can reach over 70%. Significant pain relief effects can be observed within 1-2 hours after administration, and the onset speed is much faster than traditional oral analgesics. After the first administration, the VAS pain score of the affected limb can decrease by 3-4 points in most patients, rapidly reducing the severe pain of patients in the acute phase. A large amount of clinical follow-up data has confirmed that initiating standardized intervention with salcatonin in the early stages of Sudeck's disease within 3 months can reduce the risk of the disease progressing to the chronic refractory stage by 70%, significantly reduce the long-term use of opioid analgesics, significantly improve patients' compliance with limb rehabilitation training, help affected limbs recover normal activity function faster, and ultimately achieve comprehensive improvement in patients' quality of life. Currently, this treatment plan has been widely used in CRPS I clinical practice in orthopedics and pain departments worldwide.
Information support:PubMed: Calcitonin and reflex sympathetic dystrophy syndrome.
Potential Applications
I. Diabetes‑Related Research
In recent years, research on the applications of the product has gradually expanded to the field of diabetes. A large body of animal experimental evidence has accumulated, especially regarding blood glucose regulation, improvement of insulin resistance, and prevention of related complications, demonstrating favorable potential application value. Although clinical translation is still in the exploratory stage, it provides new ideas for multi-target therapy of diabetes.The core pathological feature of diabetes is insufficient insulin secretion or insulin resistance, leading to disrupted Gls homeostasis. Long-term progression can cause pancreatic function impairment, metabolic disorders, and multi-system complications. Calcitonin salmon solution participates in glucose metabolism regulation through multiple pathways, laying the foundation for its application in diabetes.
In animal experiments, oral salcatonin has been confirmed to exert definite Gls-regulating effects. Multiple studies on rat models of obesity induced by a high-fat diet combined with ovariectomy show that after 5 weeks of oral salcatonin treatment, the body weight of rats decreases significantly by 16% to 19%, fasting Gls levels are notably improved, plasma insulin and leptin levels are reduced by approximately 50%, and the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is significantly decreased, indicating effective improvement of insulin resistance and regulation of energy and glucose homeostasis.
In addition, oral glucose tolerance test results show that salcatonin reduces the incremental area under the curve for plasma glucose and insulin by approximately 40% and 70% respectively, and significantly alleviates glucose intolerance in the portal circulation, further confirming its regulatory effect on glucose metabolism.
In short-term intervention experiments, obese male rats induced by a high-fat diet exhibit significant reductions in body weight, fasting blood glucose, and insulin levels, as well as markedly improved insulin resistance after 4 days of oral salcatonin treatment, demonstrating a certain rapid response of its hypoglycemic effect.
Beyond blood glucose regulation, salcatonin supports diabetes treatment by protecting pancreatic β‑cell function. Pancreatic β‑cells are the core cells for insulin secretion, and their impairment is a key factor in diabetes progression. Animal experiments show that salcatonin improves the secretory function of pancreatic β‑cells and reduces β‑cell apoptosis, thereby increasing insulin secretion and relieving hyperglycemia caused by insufficient insulin secretion.
Other studies have found that salcatonin can modulate the activity of insulin resistance‑related proteins through signaling pathways associated with calcitonin receptor‑like receptor (CALCRL), further improving systemic insulin sensitivity and providing a new theoretical basis for its mechanism of glucose metabolism regulation.
It should be clarified that current research on salcatonin in diabetes is still mainly at the animal experimental stage, and further exploration is needed for clinical application. Some early clinical studies show that salcatonin infusion may affect blood glucose and insulin levels in healthy individuals.
For example, infusion under basal conditions significantly increases blood glucose and decreases serum insulin levels, while after intravenous glucose loading, both glucose utilization and insulin response are reduced.
This suggests that its effects in humans may be more complex, requiring large‑sample, long‑term clinical studies to determine the eligible population, dosage, and safety.In addition, the route of administration may affect its hypoglycemic effect. Oral formulations show favorable tolerability and hypoglycemic effects in animal experiments, whereas research on injectable formulations is limited. Further optimization of dosing regimens is needed in the future to promote clinical translation. Overall, research on salcatonin in diabetes provides an important direction for expanding its application scope, and it is expected to become a new option for adjuvant diabetes therapy as research progresses
Information support:PubMed: Effects of salmon calcitonin on blood glucose and insulin levels under basal conditions and after intravenous glucose load; PubMed: Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats.
Information support:Interpretation of Expert Consensus on Salcatonin in the Treatment of Osteoporotic Fractures (2008).
Pharmacokinetics
The pharmacokinetic profile of the product is well‑defined, with absorption, distribution, metabolism, and excretion significantly affected by the route of administration. The clinically common intramuscular and subcutaneous routes present favorable pharmacokinetic advantages.As a polypeptide hormone, it is easily degraded by gastric juice after oral administration with extremely low bioavailability, so injection is the main clinical route. The absolute bioavailability is approximately 70% after intramuscular or subcutaneous administration, with peak plasma concentration reached at about 1 hour. In healthy volunteers, the peak plasma concentration after intramuscular injection is about 2.31–2.44 μg·L⁻¹, with a time to peak of 48.75–52.50 minutes.
Its apparent volume of distribution is 0.15–0.3 L/kg, with 30%–40% of the drug bound to plasma proteins.It distributes widely in the body and can cross the blood‑brain barrier to exert central analgesic effects. The elimination half‑life is 70–90 minutes, with metabolism and excretion mainly via the kidneys. 95% of the drug and its metabolites are excreted by the kidneys, with only 2% excreted in unchanged form. Patients with renal dysfunction may experience drug accumulation and require dosage adjustment.In addition, the bioavailability of the nasal spray formulation is about 50% that of the injection, with a half‑life of approximately 20 minutes. The appropriate route can be selected clinically according to patient tolerance.
Information support:National Medical Products Administration: Pharmacology, Toxicology and Pharmacokinetics of Salmotonin; Wanfang Medical Network: Study on Bioactivity and Human Bioavailability of Domestic Salmon Calcitonin Injection; Yiyao Kantle Pharmacy: Package Insert of Miacalcic (Salcatonin Injection).
Common adverse reactions and their management
Adverse reactions of the nervous system: dizziness, headache, facial flushing accompanied by a sensation of fever, etc. These are mostly transient and occur shortly after administration, with a short duration. Usually, there is no need to discontinue the medication, and symptoms can resolve spontaneously after rest. If severe symptoms such as severe dizziness, vertigo, and tinnitus occur, the medication should be discontinued immediately and medical attention should be sought promptly.
Rare adverse reactions: polyuria, chills, anaphylaxis, etc. Anaphylaxis includes local reactions at the injection site, generalized skin reactions, and in some patients, tachycardia, hypotension, collapse, and even anaphylactic shock may occur. If anaphylaxis occurs, the drug should be discontinued immediately and anti-allergic treatment should be administered. In severe cases, emergency treatment is required.
Information support:Salmon Calcitonin Injection Instruction by the National Medical Products Administration; Gutongning® Salmon Calcitonin Injection by Beijing SL Pharmaceutical Co., Ltd.
Analytical methods for Calcitonin Salmon Solution focus on the accurate determination of drug purity, content, and related substances. Combined with its characteristics as a polypeptide hormone, common methods are divided into content assay and qualitative identification, balancing accuracy and practicality, and are widely used in pharmaceutical quality control and clinical testing.
Content determination is mainly performed by High‑Performance Liquid Chromatography (HPLC), which features good separation efficiency and high sensitivity, effectively distinguishing the main drug peak from impurity peaks. In accordance with relevant specifications of the Chinese Pharmacopoeia, octadecylsilyl‑bonded silica gel is used as the filler, and the mobile phase ratio is optimized to achieve effective separation of salcatonin from degradation products.The content is calculated by the external standard method to ensure accurate and reliable test results.
Qualitative identification commonly uses immunoradiometric assay. Based on the specific antigen‑antibody binding principle, the test sample reacts with anti‑salcatonin antibody and labeled antibody to form immune complexes.
After washing to remove unbound labeled antibody, the radioactivity of the complexes is measured, and qualitative judgment is completed by comparison with the standard curve. This method has high specificity and can effectively distinguish salcatonin from similar substances such as human calcitonin.
In addition, some studies use high‑performance capillary electrophoresis for auxiliary testing, which can rapidly separate trace impurities in the drug and compensate for the shortcomings of HPLC in the detection of small‑molecule impurities. In clinical testing, appropriate methods can be selected according to testing needs to ensure pharmaceutical quality and clinical medication safety.
Information support:National Medical Products Administration: Quality Standards for Salmotonin; Douyin Encyclopedia: Calcitonin Assay; Chinese Pharmacopoeia 2020 Edition Volume II.
Hot Tags: calcitonin salmon solution, China calcitonin salmon solution manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, PT 141 Powder, glp1 shot, etelcalcetide structure
